Overview
Oxtriphylline is the choline salt form of theophylline. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Its main physiological reponse is to dilate the bronchioles. As such, oxytriphylline is indicated mainly for asthma, bronchospasm, and COPD (i.e. all the same indications as the other theophyllines). It is marketed under the name Choledyl SA, and several forms of oxytriphylline have been discontinued. In the US, oxtriphylline is no longer available.
Indication
Used to treat the symptoms of asthma, bronchitis, COPD, and emphysema.
Associated Conditions
- Bronchoconstriction
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| PMS OXTRIPHYLLINE SYR PEDIATRIC 10MG/ML | 00792934 | Syrup - Oral | 10 MG / ML | 12/31/1996 | |
| APO OXTRIPHYLLINE TAB 200MG | 00441732 | Tablet - Oral | 200 MG | 12/31/1982 | |
| CHOLEDYL | searchlight pharma inc | 00476366 | Solution - Oral | 100 MG / 5 ML | 12/31/1976 |
| NOVO-TRIPHYL TAB 200MG | novopharm limited | 00458716 | Tablet - Oral | 200 MG | 12/31/1981 |
| APO OXTRIPHYLLINE TAB 300MG | 00511692 | Tablet - Oral | 300 MG | 12/31/1982 | |
| NOVO-TRIPHYL TAB 100MG | novopharm limited | 00458708 | Tablet - Oral | 100 MG | 12/31/1981 |
| OXTRIPHYLLINE TAB 300MG | PRO DOC LIMITEE | 00589942 | Tablet - Oral | 300 MG / TAB | 12/31/1983 |
| CHOLEDYL EXPECTORANT | searchlight pharma inc | 00476374 | Solution - Oral | 100 MG / 5 ML | 12/31/1981 |
| CHOLEDYL SA TABLETS 600MG | erfa canada 2012 inc | 00536709 | Tablet (Extended-Release) - Oral | 600 MG | 12/31/1982 |
| CHOLEDYL PEDIATRIC SYR 50MG/5ML | parke-davis division, warner-lambert canada inc. | 00476390 | Syrup - Oral | 50 MG / 5 ML | 12/31/1981 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.